Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Thursday

Protara Therapeutics (NASDAQ:TARA - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts expect Protara Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protara Therapeutics Stock Performance

Shares of TARA opened at $5.66 on Thursday. The firm has a market cap of $311.64 million, a P/E ratio of -4.29 and a beta of 1.53. Protara Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The business has a 50-day moving average of $5.37 and a 200 day moving average of $5.71.

Analysts Set New Price Targets

TARA has been the subject of several recent research reports. JPMorgan Chase & Co. initiated coverage on shares of Protara Therapeutics in a research note on Wednesday, March 4th. They issued an "overweight" rating and a $27.00 target price for the company. TD Cowen reissued a "buy" rating on shares of Protara Therapeutics in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. HC Wainwright boosted their price objective on Protara Therapeutics from $23.00 to $27.00 and gave the company a "buy" rating in a research note on Wednesday, April 29th. Finally, Piper Sandler started coverage on Protara Therapeutics in a research note on Wednesday, January 7th. They issued an "overweight" rating and a $24.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $24.75.

Insider Activity at Protara Therapeutics

In other news, insider Jacqueline Zummo sold 22,598 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total value of $118,865.48. Following the transaction, the insider owned 95,961 shares of the company's stock, valued at $504,754.86. This represents a 19.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors have recently made changes to their positions in TARA. Geode Capital Management LLC increased its holdings in shares of Protara Therapeutics by 114.7% in the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company's stock worth $2,256,000 after buying an additional 397,822 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Protara Therapeutics in the 2nd quarter worth $46,000. American Century Companies Inc. increased its holdings in shares of Protara Therapeutics by 69.8% in the 2nd quarter. American Century Companies Inc. now owns 61,554 shares of the company's stock worth $187,000 after buying an additional 25,305 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Protara Therapeutics in the 2nd quarter worth $102,000. Finally, Invesco Ltd. bought a new position in shares of Protara Therapeutics in the 2nd quarter worth $73,000. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.